Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2021 Aug 17;54(9):2159–2166.e6. doi: 10.1016/j.immuni.2021.08.013

A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants

Aaron J Schmitz 1,10, Jackson S Turner 1,10, Zhuoming Liu 2,10, Julian Q Zhou 1, Ishmael D Aziati 3, Rita E Chen 1,3, Astha Joshi 3, Traci L Bricker 3, Tamarand L Darling 3, Daniel C Adelsberg 4, Clara G Altomare 4, Wafaa B Alsoussi 1,2, James Brett Case 3, Laura A VanBlargan 3, Tingting Lei 1, Mahima Thapa 1, Fatima Amanat 4,5, Trushar Jeevan 6, Thomas Fabrizio 6, Jane A O’Halloran 3, Pei-Yong Shi 7, Rachel M Presti 3,8, Richard J Webby 6, Florian Krammer 4, Sean PJ Whelan 2, Goran Bajic 4, Michael S Diamond 1,2,3,8,9, Adrianus CM Boon 1,2,3,∗, Ali H Ellebedy 1,2,8,9,11,∗∗
PMCID: PMC8367776  NIHMSID: NIHMS1735029  PMID: 34464596

Abstract

The emergence of SARS-CoV-2 antigenic variants with increased transmissibility is a public health threat. Some variants show substantial resistance to neutralization by SARS-CoV-2 infection- or vaccination-induced antibodies. Here, we analyzed receptor binding domain-binding monoclonal antibodies derived from SARS-CoV-2 mRNA vaccine-elicited germinal center B cells for neutralizing activity against the WA1/2020 D614G SARS-CoV-2 strain and variants of concern. Of five monoclonal antibodies that potently neutralized the WA1/2020 D614G strain, all retained neutralizing capacity against the B.1.617.2 variant, four also neutralized the B.1.1.7 variant, and only one, 2C08, also neutralized the B.1.351 and B.1.1.28 variants. 2C08 reduced lung viral load and morbidity in hamsters challenged with the WA1/2020 D614G, B.1.351, or B.1.617.2 strains. Clonal analysis identified 2C08-like public clonotypes among B cells responding to SARS-CoV-2 infection or vaccination in 41 out of 181 individuals. Thus, 2C08-like antibodies can be induced by SARS-CoV-2 vaccines and mitigate resistance by circulating variants of concern.

Keywords: neutralizing antibodies, SARS-CoV-2, public clone, hamster, B cell, spike protein, receptor binding domain, mRNA vaccine, germinal center, lymph node

Graphical abstract

graphic file with name fx1_lrg.jpg

Open in a new tab

SARS-CoV-2 variants with increased transmissibility are a public health threat. Schmitz et al. characterize 2C08, a human monoclonal antibody derived from a SARS-CoV-2 vaccine-induced germinal center B cell. 2C08 possesses a broad and potent neutralization capacity and protects hamsters against challenge with D614G, B.1.351, or B.1.617.2 strains. Public 2C08-like clones can be elicited by both SARS-CoV-2 infection and vaccination.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly pathogenic coronavirus that first emerged in Wuhan, China in late 2019 (Chan et al., 2020; Li et al., 2020). The virus quickly spread to multiple continents, leading to the coronavirus disease 2019 (COVID-19) pandemic. As of August 4th, 2021, SARS-CoV-2 has caused more than 190 million confirmed infections, leading to more than four million deaths (World Health Organization). The damaging impact of the morbidity and mortality caused by the COVID-19 pandemic has triggered a global effort toward developing SARS-CoV-2 countermeasures. These campaigns led to the rapid development and deployment of antibody-based therapeutics (immune plasma therapy, monoclonal antibodies [mAbs]) and vaccines (lipid nanoparticle-encapsulated mRNA, virus-inactivated, and viral-vectored platforms) (Chen et al., 2021a; Gottlieb et al., 2021; Krammer, 2020; U.S. Food & Drug Administration, 2021; Weinreich et al., 2021). The high efficacy of mRNA-based vaccines in particular has raised hope for ending the pandemic (Baden et al., 2021; Dagan et al., 2021; Polack et al., 2020). However, the emergence of multiple SARS-CoV-2 variants that are antigenically distinct from the early circulating strains used to develop the first generation of vaccines has raised concerns for compromised vaccine-induced protective immunity (Davies et al., 2021; Nonaka et al., 2021; Tegally et al., 2021). Indeed, multiple studies demonstrate that these variants show reduced neutralization in vitro by antibodies elicited in humans in response to SARS-CoV-2 infection or vaccination (Chen et al., 2021b; Liu et al., 2021a; Wang et al., 2021a, 2021b). These observations highlight the need for better understanding of the breadth of SARS-CoV-2 vaccine-induced antibody responses and possible adjustments of prophylactic and therapeutic reagents to combat emerging variants.

SARS-CoV-2 entry into host cells is mediated primarily by the binding of the viral spike (S) protein through its receptor binding domain (RBD) to the cellular receptor, human angiotensin-converting enzyme 2 (hACE2) (Zhou et al., 2020). Thus, the S protein is a critical target for antibody-based therapeutics to prevent SARS-CoV-2 virus infection and limit its spread. Indeed, the RBD is recognized by many potently neutralizing monoclonal antibodies (Alsoussi et al., 2020; Brouwer et al., 2020; Kreer et al., 2020; Robbiani et al., 2020; Tortorici et al., 2020; Yuan et al., 2020; Zost et al., 2020a, 2020b). The Pfizer-BioNTech SARS-CoV-2 mRNA vaccine (BNT162b2) encodes the full-length prefusion stabilized SARS-CoV-2 S protein and induces robust serum binding and neutralizing antibody responses in humans (Jackson et al., 2020; Polack et al., 2020). We recently described the S-specific germinal center B cell response in aspirates from the draining axillary lymph nodes induced by BNT162b2 vaccination in healthy adults (Turner et al., 2021). We verified the specificity of the germinal center response by generating a panel of recombinant human mAbs from single cell-sorted S-binding germinal center B cells isolated from three participants. The majority of these vaccine-induced antibodies are directed against the RBD (Turner et al., 2021).

Here, we assessed the capacity of these anti-RBD mAbs to recognize and neutralize recently emerged SARS-CoV-2 variants. One mAb, 2C08, potently neutralized the WA1/2020 D614G SARS-CoV-2 strain and also neutralized the B.1.351 and B.1.1.28 variants. 2C08 reduced lung viral load and morbidity in hamsters challenged with the WA1/2020 D614G, B.1.351, or B.1.617.2 strains. Clonal analysis identified 2C08-like public clonotypes among B cells responding to SARS-CoV-2 infection or vaccination in 41 out of 181 individuals.

Results

mAb 2C08 potently neutralizes diverse SARS-CoV-2 strains

From a pool of S-binding germinal center B cell-derived mAbs, we selected 13 human anti-RBD mAbs that bound avidly to the historically circulating WA1/2020 D614G SARS-CoV-2 strain referred to hereafter as the D614G strain (Korber et al., 2020; Turner et al., 2021). We assessed mAbs binding to recombinant RBDs derived from the D614G strain and four SARS-CoV-2 variants—B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), and B.1.617.2 (delta)—by enzyme-linked immunosorbent assay (ELISA). Only one mAb, 1H09, showed decreased binding to the RBD derived from the B.1.1.7 variant. Four additional mAbs (4B05, 1B12, 2B06, and 3A11) completely lost or showed substantially reduced binding to the B.1.351 and B.1.1.28 variant RBDs, and 4B05 also lost binding to the B.1.617.2 variant. The remaining eight mAbs showed equivalent binding to RBDs from all tested strains (Figure 1 A). We next examined the in vitro neutralization capacity of the 13 mAbs against the D614G SARS-CoV-2 strain using a high-throughput focus reduction neutralization test (FRNT) with authentic virus (Case et al., 2020). Only five mAbs (2C08, 1H09, 1B12, 2B06, and 3A11) showed high neutralization potency against D614G with 80% neutralization values of less than 100 ng/mL. We then assessed the ability of these five mAbs to neutralize the B.1.1.7, B.1.351, B.1.1.28, and B.1.617.2 variants. Consistent with the RBD binding data, 1H09 failed to neutralize any of the emerging variants except B.1.617.2, whereas 1B12, 2B06, and 3A11 neutralized B.1.1.7 and B.1.617.2 but not the B.1.351 and B.1.1.28 variants (Figure 1B). One antibody, 2C08, potently neutralized the five SARS-CoV-2 strains we tested, with half-maximal inhibitory concentration of 0.3 ng/mL for B.1.617.2 and approximately 5 ng/mL for all others (Figure 1B; Table S1), indicating that it recognized conserved residues in the RBD. We also tested 2C08 against three additional variants, B.1.429, B.1.222, and B.1.1.298, and found that it potently neutralized all three variants (Figure S1A). Altogether, these results indicated 2C08 recognized and neutralized diverse strains of SARS-CoV-2.

Figure 1.

Figure 1

Open in a new tab

mAb 2C08 potently neutralizes diverse SARS-CoV-2 strains

(A and B) ELISA binding to recombinant RBD from (A) and neutralizing activity in Vero-TMPRSS2 cells against (B) indicated SARS-CoV-2 strains by the indicated mAbs. ELISA binding to D614G RBD previously reported in (Turner et al., 2021). Baseline for area under the curve was set to the mean + three times the standard deviation of background binding to bovine serum albumin. Dotted lines indicate limit of detection. Bars indicate mean ± SEM. Results are from one experiment performed in duplicate (A, D614G and B.1.617.2) or in singlet (A, B.1.1.7, B.1.351, and B.1.1.28), or two experiments performed in duplicate (B). See also Figure S1 and Table S1.

mAb 2C08 protects hamsters from D614G and variant SARS-CoV-2 challenge

To assess the protective capacity of 2C08 in vivo, we utilized a hamster model of SARS-CoV-2 infection (Sia et al., 2020). We evaluated the prophylactic efficacy of 2C08 against the D614G strain, a fully infectious recombinant chimeric SARS-CoV-2 with the B.1.351 S gene in the WA1/2020 backbone (Wash-B.1.351; D80A, 242-244 deletion, R246I, K417N, E484K, N501Y, D614G and A701V) (Chen et al., 2021b), and the B.1.617.2 strain in 5-to-6-week-old male Syrian hamsters. Animals treated with 2C08 did not lose weight after viral challenge and started to gain weight (relative to starting weight) 3 days post infection (dpi). In contrast, animals treated with the isotype control mAb started losing weight 2 dpi. The average weights between the isotype- and 2C08-treated animals differed by 7.1% 3 dpi (p < 0.001) and 10.4% 4 dpi (p < 0.001) for the D614G challenge, by 6.8% 3 dpi (p = 0.095) and 9.1% 4 dpi (p = 0.056) for the Wash-B.1.351 challenge, and by 8.5% 3 dpi (p = 0.008) and 9.7% 4 dpi (p = 0.008) for the B.1.617.2 challenge (Figure 2 A). Consistent with the weight loss data, 2C08 treatment reduced viral RNA by more than 10,000-fold in the lungs of the D614G- and B.1.617.2-challenged hamsters (p < 0.001 and p = 0.008, respectively) and by approximately 1,000-fold in those challenged with Wash-B.1.351 (p = 0.008) 4 dpi compared with the isotype control mAb groups (Figure 2B). Prophylactic treatment also significantly reduced infectious virus titers for all strains detected in the lungs 4 dpi (p < 0.001 for D614G, p = 0.008 for both variants) (Figure 2C). Overall, prophylaxis with 2C08 substantially decreased morbidity and viral infection in lower respiratory tissues upon challenge with SARS-CoV-2 strains with S genes corresponding to those circulating early in the pandemic and two key variants.

Figure 2.

Figure 2

Open in a new tab

mAb 2C08 protects hamsters from SARS-CoV-2 challenge

(A–C) Percent weight change over time (A) and viral RNA (B) and infectious virus titer (C) in lung homogenates 4 dpi of hamsters that received 5 mg/kg isotype (black) or 2C08 (gray) one day prior to intranasal challenge with 5×105 FFU of D614G, (left), Wash-B.1.351 (center), or B.1.617.2 (right) SARS-CoV-2. In (A), symbols indicate mean ± SEM. In (B and C), bars indicate geometric mean ± geometric SD, and each symbol represents one hamster. D614G data are from two experiments, n = 10 per condition; variant data are from one experiment, n = 5 per condition. p values from two-tailed Mann-Whitney U tests.

2C08 recognizes a public epitope in SARS-CoV-2 RBD

To define the RBD residues targeted by 2C08, we used VSV-SARS-CoV-2-S chimeric viruses (S from D614G strain) to select for variants that escape 2C08 neutralization as previously described (Case et al., 2020; Liu et al., 2021b). We performed plaque assays on Vero cells with 2C08 in the overlay, purified the neutralization-resistant plaques, and sequenced the S genes (Figures S2A and S2B). Sequence analysis identified the S escape mutations G476D, G476S, G485D, F486P, F486V, and N487D—all of which were within the RBD and mapped to residues involved in hACE2 binding (Figure 3 A). We confirmed the specificity of 2C08 for the hACE2-binding site of RBD in bio-layer interferometry (BLI)-based competition assays (Figure 3B). To determine whether any of the 2C08 escape mutants we isolated were represented among SARS-CoV-2 variants circulating in humans, we screened publicly available genome sequences of SARS-CoV-2 (Shu and McCauley, 2017; Singer et al., 2020). Using 829,521 genomes from Global Initiative on Sharing Avian Influenza Data (GISAID), we calculated each substitution frequency in the identified residues site. Of the six escape variants we identified, four were detected among circulating isolates of SARS-CoV-2. The frequency of these substitutions among clinical isolates detected so far was exceedingly rare, with the escape variants representing less than 0.008% of sequenced viruses. In comparison, the D614G substitution was present in 49% of sequenced isolates (Figure S2C).

Figure 3.

Figure 3

Open in a new tab

mAb 2C08 recognizes a public epitope in SARS-CoV-2 RBD

(A) Structure of RBD (from PDB 6M0J) with hACE2 footprint highlighted in magenta and amino acids whose substitution confers resistance to 2C08 in plaque assays highlighted in yellow. (B and C) BLI-based competition of 2C08 Fab with hACE2 (B) or S2E12 Fab with 2C08 Fab (C) for RBD binding. Maximal signal (Rmax) at steady state is plotted as a function of hACE2 (B) or 2C08 Fab (C) concentration. (D and E) Sequence alignment of 2C08 with RBD-binding mAbs from SARS-CoV-2 infected patients and vaccinees that utilize the same immunoglobulin heavy- (D) and light-chain (E) variable region genes (see also Table S2). Antibody residues that contact RBD (red stars) and secondary structure elements (yellow alpha helices and blue beta strands) are calculated from the S2E12 structure (PDB ID 7K45) (Tortorici et al., 2020). See also Figures S2 and S3 and Table S2.

We noted that 2C08 targeted residues similar to those recognized by a previously described human mAb, S2E12, which was isolated from an infected patient (Tortorici et al., 2020). S2E12 shared a high sequence identity with 2C08 (95% amino acid identity) and was encoded by the same immunoglobulin heavy (IGHV1-58) and light (IGKV3-20) chain variable region genes (Table S2). Similar to 2C08, S2E12 exhibits potent neutralizing activity in vitro and protective capacity in vivo (Chen et al., 2021c). The cryoelectron microscopy structure of S2E12 in complex with S shows that the mAb recognizes an RBD epitope that partially overlaps with the hACE2 receptor footprint known as the receptor binding motif (Tortorici et al., 2020) (Figures S3A and S3B). 2C08 competed with S2E12 for RBD binding in BLI-based competition assays (Figure 3C). Moreover, 13 of 14 S2E12 heavy-chain amino acid residues that engaged the RBD were identical to those in 2C08, and electron microscopy two-dimensional (2D) classes of 2C08 in complex with S indicated that it bound RBD in fashion reminiscent of S2E12 (Figures 3D, 3E, and S3C). Altogether, these data suggest that 2C08 likely engaged the RBD in a manner similar to that of the structurally characterized S2E12. Furthermore, we identified two additional human mAbs, 253H55L and COV2-2196, that share genetic and functional features with 2C08 and have nearly identical antibody-RBD interactions as those of S2E12 (Dong et al., 2021; Zost et al., 2020a) (Figures 3D, 3E, S3A, and S3B). Dong et al. (2021) note that COV2-2196 is likely part of a public B cell clone, citing S2E12 and mAbs generated by two other groups with similar characteristics (Robbiani et al., 2020; Tortorici et al., 2020). This prompted us to conduct an expanded search for 2C08-like clonotypes and mAbs. Defining 2C08-like clones as those that shared heavy-chain V1-58 and J3 gene usage, had a CDR3 length between 15 and 17 amino acids, and had a CXC disulfide bond motif in the CDR3 (where “X” can be one or more amino acids), we identified 2 individuals in our cohort of 22 BNT162b2-vaccinated individuals who had 2C08-like clones among activated or memory B cells in peripheral blood mononuclear cells two or four weeks after the second immunization. We identified an additional 5 of 14 vaccine recipients and 34 of 145 SARS-CoV-2 convalescent individuals with 2C08-like clones among published sequences (Andreano et al., 2021; Brouwer et al., 2020; Dejnirattisai et al., 2021; Galson et al., 2020; Han et al., 2021; Kreer et al., 2020; Kreye et al., 2020; Nielsen et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Scheid et al., 2021; Tortorici et al., 2020; Wang et al., 2021b) (Table S2). The primary heavy-chain contact residues described for S2E12 were largely conserved for all mAbs (Figures 3D and 3E). Altogether, these results indicate that 2C08 targeted a conserved region of the RBD and 2C08-like clones can be generated in response to SARS-CoV-2 infection or vaccination.

Discussion

Cloning and expression of recombinant human mAbs from single-cell-sorted B cells is an established method for generating potential therapeutics against human pathogens. The source cells are predominantly plasmablasts or memory B cells isolated from blood after infection or vaccination (Wilson and Andrews, 2012). Here, we characterized 2C08, a SARS-CoV-2 vaccine-induced mAb cloned from a germinal center B cell isolated from a draining axillary lymph node sampled from a healthy adult after receiving their second dose of mRNA-based vaccine (Turner et al., 2021). 2C08 targeted the receptor binding motif within the RBD of SARS-CoV-2 S protein and blocked infection by circulating SARS-CoV-2 and emerging variants of concern both in vitro and in vivo.

2C08 is a “public” mAb, meaning that it is encoded by multiple B cell clonotypes isolated from different individuals that share similar genetic features (Dong et al., 2021). Public antibody responses in humans are observed after many infections, including SARS-CoV-2 infection (Dejnirattisai et al., 2021; Dong et al., 2021; Galson et al., 2020; Pappas et al., 2014; Robbiani et al., 2020; Wheatley et al., 2015; Wu et al., 2011; Zhou et al., 2015). In the case of 2C08-like clonotypes, the mAbs not only share the immunoglobulin heavy- and light-chain variable region genes, but also have highly similar CDRs and are functionally similar. Several have been shown to bind RBD and neutralize D614G as well as the B.1.1.7 and B.1.351 variants. 2C08-like mAbs can be found in SARS-CoV-2-infected patients independently of demographics or severity of infection. Robbiani et al. isolate 2C08-like mAbs from four of six infected individuals (Robbiani et al., 2020). Tortorici et al. and Zost et al. detect a 2C08-like antibody in one or both of two infected individuals they examine, respectively, whereas Kreer et al. detect a 2C08-like clone in two of twelve patients, in one of whom it is expanded (Kreer et al., 2020; Tortorici et al., 2020; Zost et al., 2020a). Nielsen et al. identify 2C08-like rearrangements in sequences derived from four of thirteen SARS-CoV-2 patients (Nielsen et al., 2020). Wang et al. isolate 2C08-like mAbs from five of fourteen individuals who received a SARS-CoV-2 mRNA-based vaccine (Wang et al., 2021b). While 2C08-like clones can respond to both SARS-CoV-2 infection and vaccination, the frequency with which they are detected varies among studies. This may be because of variation in sampling depth and whether analyzed sequences are enriched for S- or RBD-binding clones. It remains to be determined what fraction of the antibody responses induced by SARS-CoV-2 vaccines in humans are comprised of public, potently neutralizing, 2C08-like antibodies that are minimally impacted by the mutations found in the variants of concern to date. It is important to note that at least one 2C08-like mAb, COV2-2196, is currently being developed for clinical use (Dong et al., 2021).

Most SARS-CoV-2 vaccine-induced anti-RBD mAbs in our study also recognized RBDs from the recent variants. Notably, all of the five neutralizing antibodies retained their neutralizing capacity against the recent B.1.617.2 variant. It is of some concern, however, that four of the five neutralizing anti-RBD mAbs lost their activity against the B.1.351 and B.1.1.28 variants. This was consistent with the data reported by Wang et al., which showed that the neutralizing activity of 14 of 17 vaccine-induced anti-RBD mAbs was abolished by mutations associated with these variants (Wang et al., 2021b). We note that somewhat higher levels of lung viral RNA were recovered from the 2C08-treated animals challenged with the Wash-B.1.351 variant compared with those challenged with the D614G or B.1.617.2 strains. This was unexpected given the similar in vitro potency of 2C08 against all three viruses and its capacity to protect animals from all challenge groups against weight loss equivalently. One possibility is that 2C08 more readily selected for a partial escape mutant among viruses displaying the B.1.351 variant spike than the WA1/2020 D614G or B.1.617.2 spikes. Indeed, we found that virus recovered from the lungs of the B.1.351-challenged hamster with the highest viral titer in the 2C08-treated group had developed a G476S mutation. Although mutations such as these that abrogate 2C08 binding currently are rare among clinical isolates, viruses carrying the F486L mutation have been isolated from farmed mink and could be transmitted to humans (Oude Munnink et al., 2021). More broadly, the selective pressure of vaccination and monoclonal antibody therapies as they are approved could drive the emergence of viral escape variants, reducing the effectiveness of current vaccines.

Given the germinal center B cell origin of 2C08, the binding of 2C08-related clones could be refined through somatic hypermutation, and their descendants could become part of the high-affinity memory B cell and long-lived plasma cell compartments that confer durable protective immunity. Together, these data suggest that first-generation SARS-CoV-2 mRNA-based vaccines can induce public antibodies with robust neutralizing and potentially durable protective activity against historically circulating and emerging SARS-CoV-2 variants.

Limitations of the study

We may have underestimated the frequency of 2C08-like clones among the 22 BNT162b2-vaccinated individuals we examined, as our enrichment strategy excluded resting non-class switched memory B cells. 2C08-like clones may have also been present at lower frequency than we sampled or have arisen later in the response. These same caveats apply to the sequences that we analyzed from published studies of SARS-CoV-2 infected and vaccinated individuals. Another limitation of our study is that we analyzed only a small number of antibodies that targeted the RBD. More extensive analyses with larger numbers of mAbs that target the RBD and non-RBD sites will be needed to precisely determine the fraction of the vaccine-induced neutralizing antibody response that is compromised because of antigenic changes in emerging SARS-CoV-2 variants of concern.

STAR★Methods

Key resources table

REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
HRP-conjugated Goat anti-human IgG Jackson ImmuoResearch Cat# 109-035-088
07.2C08 Turner et al., 2021 GenBank: MW926400, MW926423
07.3D07 Turner et al., 2021 GenBank: MW926401, MW926424
07.4A07 Turner et al., 2021 GenBank: MW926402, MW926425
07.2A10 Turner et al., 2021 GenBank: MW926399, MW926422
07.1H09 Turner et al., 2021 GenBank: MW926397, MW926420
07.1A11 Turner et al., 2021 GenBank: MW926396, MW926419
07.4B05 Turner et al., 2021 GenBank: MW926403, MW926426
22.1B04 Turner et al., 2021 GenBank: MZ292499, MZ292500
22.1B12 Turner et al., 2021 GenBank: MW926410, MW926433
22.1E11 Turner et al., 2021 GenBank: MW926412, MW926435
22.2A06 Turner et al., 2021 GenBank: MW926414, MW926437
22.2B06 Turner et al., 2021 GenBank: MW926415, MW926438
22.3A11 Turner et al., 2021 GenBank: MW926418, MW926441
S2E12 Fab Tortorici et al., 2020 N/A
SARS2-2 Liu et al., 2021b N/A
SARS2-11 Liu et al., 2021b N/A
SARS2-16 Liu et al., 2021b N/A
SARS2-31 Liu et al., 2021b N/A
SARS2-38 Liu et al., 2021b N/A
SARS2-57 Liu et al., 2021b N/A
SARS2-71 Liu et al., 2021b N/A
HRP-conjugated goat anti-mouse IgG Millipore Sigma Cat# 12-349
IgD-PE BioLegend Clone IA6-2; Cat# 348204
Bacterial and virus strains
SARS-CoV-2 WA1/2020 D614G, Wash-B.1.351, Wash-B.1.1.28 Chen et al., 2021b N/A
SARS-CoV-2 B.1.1.7 Chen et al., 2021b N/A
SARS-CoV-2 B.1.617.2 Gift of R. Webby (St Jude Children Research Hospital) N/A
SARS-CoV-2 B.1.429 C. Chiu and R. Andino labs (UCSF) N/A
SARS-CoV-2 B.1.222 BEI Cat# NR-53945
SARS-CoV-2 B.1.298 BEI Cat# NR-53953
Biological samples
PBMC from SARS-CoV-2 vaccinated individuals Ellebedy Lab N/A
Chemicals, peptides, and recombinant proteins
NEBNext Immune Sequencing Kit (Human) New England Biolabs Cat# E6320
SARS-CoV-2-RBD Amanat et al., 2020 GenBank: MT380724.1
B.1.1.7 RBD Amanat et al., 2021 N/A
B.1.351 RBD Amanat et al., 2021 N/A
B.1.1.248 RBD Amanat et al., 2021 N/A
B.1.617.2 RBD Krammer Lab, Mount Sinai N/A
Spike HexaPro Hsieh et al., 2020 Addgene (ID: 154754)
o-Phenylenediamine dihydrochloride Sigma-Aldrich Cat# P8787
Pierce HRV 3C Protease ThermoScientific Cat# 88946
TALON Metal Affinity Resin Clontech Cat# 635652
TrueBlue peroxidase substrate Sera-Care KPL Cat# 5510-0030
Critical commercial assays
Ni-NTA (NTA) Biosensors Sartorius Corporation Cat# 18-5101
RNeasy Plus Micro Kit QIAGEN Cat# 74034
RNeasy Mini Kit QIAGEN Cat# 74106
OneStep RT-PCR Kit QIAGEN Cat# 210212
αPE Nanobeads BioLegend Cat# 480092
EasySep Human B Cell Isolation Kit Stemcell Cat# 17954
ExpiFectamine 293 Transfection Kit ThermoFisher Cat# A14525
E.Z.N.A.® Total RNA Kit I Omega Cat# R6834-02
TaqMan™ RNA-to-CT 1-Step Kit ThermoFisher Cat# 4392938
Deposited data
Raw bulk sequencing data from vaccinees Turner et al., 2021 SRA: PRJNA731610
Raw bulk sequencing data from vaccinees This paper SRA: PRJNA741267
Processed bulk sequencing data from vaccinees This paper Zenodo: https://doi.org/10.5281/zenodo.5040099
368-07_b7 Vaccinee Immunoglobulin Heavy Chain This paper GenBank: MZ615310
368-28_b30 Vaccinee Immunoglobulin Heavy Chain This paper GenBank: MZ615309
Processed bulk sequencing data from vaccinees Goel et al., 2021 iReceptor Gateway: PRJNA715378
Processed bulk sequencing data from infected individuals Galson et al., 2020 Zenodo: https://doi.org/10.5281/zenodo.3899008
Processed single-cell paired data from infected individuals Scheid et al., 2021 https://singlecell.broadinstitute.org/single_cell/study/SCP1317/sars-cov-2-antibodies
Experimental models: Cell lines
Vero-TMPRSS2 cells Zang et al., 2020 N/A
Expi293F Thermo Fisher GIBCO Cat# A14527
Vero-Creanga Gift from Andrea Craenga and Barney Graham at the National Institute of Health N/A
Experimental models: Organisms/strains
LVG Golden Syrian Hamster Charles Rivers Laboratories Cat# Crl:LVG(SYR)
Oligonucleotides
Template switch sequences and constant region primers for bulk sequencing Turner et al., 2021 N/A
SARS-CoV-2 N F: 5'-ATGCTGCAATCGTGCT
ACAA-3'		 Integrated DNA technologies N/A
SARS-CoV-2 N R: 5'-GACTGCCGCCTCTGCTC-3' Integrated DNA technologies N/A
SARS-CoV-2 N Probe: 5'-/56-FAM/TCAAGGAAC/ZEN/AACATTGCCAA/3IABkFQ/-3' Integrated DNA technologies N/A
Recombinant DNA
pCAGGS SARS-CoV-2 RBD Amanat et al., 2020 N/A
pCAGGS SARS-CoV-2 variant RBD B.1.1.7 Amanat et al., 2021 N/A
pCAGGS SARS-CoV-2 variant RBD B.1.351 Amanat et al., 2021 N/A
pCAGGS SARS-CoV-2 variant RBD B.1.1.248 Amanat et al., 2021 N/A
pCAGGS SARS-CoV-2 variant RBD B.1.617.2 Krammer Lab, Mount Sinai N/A
pVRC S2E12 heavy and light chain expression plasmids This study N/A
Software and algorithms
GraphPad Prism v9.0.2 GraphPad Software www.graphpad.com
BLItz Pro 1.3.1.3 Forté Bio www.fortebio.com/blitz.html
Aline v011208 Bond and Schüttelkopf, 2009 https://bondxray.org/software/aline.html
PyMol v2.1.0 Schrodinger https://pymol.org/2/
Analysis code This paper https://doi.org/10.5281/zenodo.5040146
MUSCLE v3.8.31 Edgar, 2004 https://www.ebi.ac.uk/Tools/msa/muscle/
Alakazam v1.1.0 Gupta et al., 2015 https://changeo.readthedocs.io/
Other
iReceptor Gateway Corrie et al., 2018 https://gateway.ireceptor.org/
Nunc-Immuno™ Maxisorp™ 96 well ELISA plates Thermo Fisher Cat#439454
Open in a new tab

Resource availability

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Ali H. Ellebedy (ellebedy@wustl.edu).

Materials availability

This study did not generate new unique reagents.

Experimental model and subject details

Cells

Expi293F cells were cultured in Expi293 Expression Medium (GIBCO). Vero-TMPRSS2 cells (a gift from S. Ding, Washington University School of Medicine) were cultured at 37°C in Dulbecco’s Modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES pH 7.3, 1 mM sodium pyruvate, 1 × non-essential amino acids, 5 μg/mL of blasticidin, and 100 U/mL of penicillin–streptomycin. Vero-Creanga cells, a gift from A. Creanga and B. Graham, NIH, were cultured at 37°C in Dulbecco’s Modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES pH 7.3, 100 U/mL of penicillin–streptomycin, and 10 μg/mL of puromycin.

Viruses

The WA1/2020 recombinant strains with substitutions D614G, B.1.351-, and B.1.1.28-variant spike genes introduced into an infectious cDNA clone of the 2019n-CoV/USA_WA1/2020 strain, were previously described (Chen et al., 2021b; Plante et al., 2021). The B.1.617.2 (Edara et al., 2021), B.1.1.7, B.1.429, B.1.222, and B.1.1.298 isolates were collected from infected individuals and propagated on Vero-TMPRSS2 cells. All viruses were subjected to next-generation sequencing as previously described to confirm the introduction and stability of substitutions (Chen et al., 2021b). All virus experiments were performed in approved biosafety level 3 (BSL3) facilities.

Antigens

Recombinant receptor binding domain of S (RBD), was expressed as previously described (Amanat et al., 2021; Stadlbauer et al., 2020). Briefly, RBD, along with the signal peptide (amino acids 1-14) plus a hexahistidine tag were cloned into mammalian expression vector pCAGGS. RBD mutants were generated in the pCAGGS RBD construct by changing single residues using mutagenesis primers. Recombinant RBDs were produced in Expi293F cells (ThermoFisher) by transfection with purified DNA using the ExpiFectamine 293 Transfection Kit (ThermoFisher). Supernatants from transfected cells were harvested 4 days post-transfection, and recombinant proteins were purified using Ni-NTA agarose (ThermoFisher), then buffer exchanged into phosphate buffered saline (PBS) and concentrated using Amicon Ultracel centrifugal filters (EMD Millipore).

Plasmid encoding the stabilized variant of the SARS-CoV-2 S, HexaPro (HP) (Hsieh et al., 2020), was a gift from Jason McLellan (University of Texas, Austin). Recombinant S was expressed in Expi293F cells grown in Expi293 medium after transfection with S-encoded plasmid DNA complexed with polyethylenamine (PEI, Polysciences). Cells were grown for 6 days before subjecting conditioned media to affinity chromatography following centrifugation and 0.2 μm filtration. The S was purified using Co2+-NTA TALON resin (Takara) followed by gel filtration chromatography on Superdex 200 Increase (GE Healthcare) in 10 mM Tris-HCl, 150 mM NaCl at pH 7.5. For cryoelectron microscopy the tags were removed using HRV 3C protease (ThermoScientific) and the protein re-purified using Co2+-NTA TALON resin to remove the protease, tag and non-cleaved protein.

Hamster studies

All procedures involving animals were performed in accordance with guidelines of the Institutional Animal Care and Use Committee of Washington University in Saint Louis. Five- to six-week old male Syrian hamsters were obtained from Charles River Laboratories and housed in an enhanced BSL3 facility at Washington University in St Louis. Animals were randomized from different litters into experimental groups and were acclimatized at the BSL3 facilities for 4-6 days prior to experiments.

Methods details

Enzyme-linked immunosorbant assay

Assays were performed in 96-well plates (MaxiSorp; Thermo). Each well was coated with 100 μL of wild-type or variant RBD or bovine serum albumin (1μg/mL) in PBS, and plates were incubated at 4°C overnight. Plates were then blocked with 0.05% Tween20 and 10% FBS in PBS. mAbs were serially diluted in blocking buffer and added to the plates. Plates were incubated for 90 min at room temperature and then washed 3 times with 0.05% Tween-20 in PBS. Goat anti-human IgG-HRP (Jackson ImmunoResearch 109-035-088, 1:2,500) was diluted in blocking buffer before adding to wells and incubating for 60 min at room temperature. Plates were washed 3 times with 0.05% Tween20 in PBS, and then washed 3 times with PBS. o-Phenylenediamine dihydrochloride substrate dissolved in phosphate-citrate buffer (Sigma-Aldrich) with H2O2 catalyst was incubated in the wells until reactions were stopped by the addition of 1 M HCl. Optical density measurements were taken at 490 nm. Area under the curve was calculated using Graphpad Prism v8.

Focus reduction neutralization test

Serial dilutions of each mAb diluted in DMEM with 2% FBS were incubated with 102 focus-forming units (FFU) of different strains or variants of SARS-CoV-2 for 1 h at 37°C. Antibody-virus complexes were added to Vero-TMPRSS2 cell monolayers in 96-well plates and incubated at 37°C for 1 h. Subsequently, cells were overlaid with 1% (w/v) methylcellulose in MEM supplemented with 2% FBS. Plates were harvested 24 h later by removing overlays and fixed with 4% PFA in PBS for 20 min at room temperature. Plates were washed and sequentially incubated with an oligoclonal pool of SARS2-2, SARS2-11, SARS2-16, SARS2-31, SARS2-38, SARS2-57, and SARS2-71 anti-S antibodies (Liu et al., 2021b) and HRP-conjugated goat anti-mouse IgG (Sigma 12-349) in PBS supplemented with 0.1% saponin and 0.1% bovine serum albumin. SARS-CoV-2-infected cell foci were visualized using TrueBlue peroxidase substrate (KPL) and quantitated on an ImmunoSpot microanalyzer (Cellular Technologies).

Hamster challenge experiments

Hamsters received intra-peritoneal (IP) injection of isotype control or mAb 2C08 24 h prior to SARS-CoV-2 challenge. Hamsters were anesthetized with isoflurane and were intranasally inoculated with 5 × 105 FFU of 2019n-CoV/USA_WA1/2020-D614G, Wash-B.1.351, or B.1.617.2 SARS-CoV-2 in 100 μL PBS. Animal weights were measured every day for the duration of experiments. Animals were euthanized 4 dpi and the lungs were collected for virological analyses. Left lung lobes were homogenized in 1 mL of PBS or DMEM, clarified by centrifugation, and used for virus titer assays.

Virus titration assays from hamster lung homogenates

Plaque assays were performed on Vero-Creanga cells in 24-well plates. Lung tissue homogenates were serially diluted 10-fold, starting at 1:10, in cell infection medium (DMEM supplemented with 2% FBS, 1mM HEPES, L-glutamine, penicillin, and streptomycin). Two hundred and fifty microliters of the diluted virus were added to a single well per dilution per sample. After 1 h at 37°C, the inoculum was aspirated, the cells were washed with PBS, and a 1% methylcellulose overlay in MEM supplemented with 2% FBS was added. Seventy-two h after virus inoculation, the cells were fixed with 4% formalin, and the monolayer was stained with crystal violet (0.5% w/v in 25% methanol in water) for 1 h at 20°C. The number of plaques were counted and used to calculate the plaque forming units/mL (PFU/mL).

To quantify viral load in lung tissue homogenates, RNA was extracted from 100 μl samples using the E.Z.N.A.® Total RNA Kit I (Omega) and eluted with 50 μl of water. Four microliters RNA was used for real-time qRT-PCR to detect and quantify N gene of SARS-CoV-2 using the TaqMan RNA-to-CT 1-Step Kit (Thermo Fisher Scientific) with the following primers and probes for the N-gene, Forward primer: ATGCTGCAATCGTGCTACAA; Reverse primer: GACTGCCGCCTCTGCTC; Probe: /56-FAM/TCAAGGAAC/ ZEN/AACATTGCCAA/3IABkFQ/. Viral RNA was expressed as gene copy numbers per mg for lung tissue homogenates, based on a standard included in the assay, which was created via in vitro transcription of a synthetic DNA molecule containing the target region of the N gene.

Selection of 2C08 mAb escape mutants in SARS-CoV-2 S

We used VSV-SARS-CoV-2-S chimera to select for SARS-CoV-2 S variants that escape mAb neutralization as described previously (Case et al., 2020; Liu et al., 2021b). Antibody neutralization-resistant mutants were recovered by plaque isolation. Briefly, plaque assays were performed to isolate the VSV-SARS-CoV-2 escape mutant on Vero cells with mAb 2C08 in the overlay. The concentration of 2C08 in the overlay was determined by neutralization assays at a multiplicity of infection (MOI) of 100. Escape clones were plaque-purified on Vero cells in the presence of 2C08, and plaques in agarose plugs were amplified on MA104 cells with the 2C08 present in the medium. Viral supernatants were harvested upon extensive cytopathic effect and clarified of cell debris by centrifugation at 1,000 x g for 5 min. Aliquots were maintained at −80°C. Viral RNA was extracted from VSV-SARS-CoV-2 mutant viruses using RNeasy Mini kit (QIAGEN), and S was amplified using OneStep RT-PCR Kit (QIAGEN). The mutations were identified by Sanger sequencing (GENEWIZ).

Bulk B cell receptor library preparation, sequencing, and processing

Activated and memory B cells were enriched from peripheral blood mononucelar cells collected two weeks after the second dose of BNT162b2 from 22 individuals by first staining with IgD-PE and MojoSort anti-PE Nanobeads (BioLegend), and then processing with the EasySep Human B Cell Isolation Kit (Stemcell) to negatively enrich IgDlo B cells. Bulk sequencing libraries of B cell receptors (BCRs) were prepared from the IgDlo enriched B cells as previously described (Turner et al., 2021). Briefly, RNA was purified from enriched IgDlo B cells using the RNeasy Plus Micro kit (QIAGEN). Reverse transcription, unique molecular identifier (UMI) barcoding, cDNA amplification, and Illumina linker addition to B cell heavy chain transcripts were performed using the human NEBNext Immune Sequencing Kit (New England Biolabs) according to the manufacturer’s instructions. High-throughput 2x300bp paired-end sequencing was performed on the Illumina MiSeq platform with a 30% PhiX spike-in according to manufacturer’s recommendations, except for performing 325 cycles for read 1 and 275 cycles for read 2. Processing of BCR bulk sequencing reads from the 22 samples and subsequent BCR genotyping were performed as previously described (Turner et al., 2021), with the exceptions that sequencing errors were corrected using the UMIs as they were without additional clustering, and that all unique consensus sequences were used for analysis without thresholding by the number of contributing reads. In addition, three samples of IgDlo B cells from PBMCs collected four weeks after secondary immunization (one each from participants 07, 20, and 22), and five previously reported samples consisting of plasmablasts sorted from PBMCs and germinal center B cells sorted from fine needle aspirates of draining axillary lymph nodes one week after secondary immunization (Turner et al., 2021), were, respectively, processed and reprocessed as previously described in (Turner et al., 2021) with the modification that all unique consensus sequences were included without thresholding by the number of contributing reads. Processed heavy chain sequences from all 30 samples (Table S3) were combined and subset to those with IGHV1-58 and IGHJ3 respectively for V and J gene annotations. Further querying was performed by requiring the sequences to have a CDR3 length of between 15 and 17 amino acids, and/or have a “CXC” disulfide bond motif in the CDR3, where “X” can be one or more amino acids. The queried sequences then underwent multiple sequence alignment using MUSCLE v3.8.31 (https://www.ebi.ac.uk/Tools/msa/muscle/) (Edgar, 2004).

Processed heavy chain bulk sequencing data (19 subjects) from Galson et al. (Galson et al., 2020) was downloaded from Zenodo (https://doi.org/10.5281/zenodo.3899008) on 2021-04-30. The data was then subset to sequences with IGHV1-58 and IGHJ3 respectively for V and J gene annotations, a nucleotide length of 48 for CDR3s, and a disulfide bond motif in the CDR3s, yielding 2,161 sequences from 12 subjects. Pairwise Hamming distances from the CDR3s of these sequences to that of 2C08 were computing using Alakazam v1.1.0 (Gupta et al., 2015).

Processed single-cell paired BCR data (14 subjects) from Scheid et al. (Scheid et al., 2021) was downloaded from the Single Cell Portal (https://singlecell.broadinstitute.org/single_cell/study/SCP1317/sars-cov-2-antibodies) on 2021-06-23. The data was then subset to cells with IGHV1-58, IGHJ3, IGKV3-20, and IGKJ1 for, respectively, heavy chain V, heavy chain J, light chain V, and light chain J gene annotations, yielding 8 cells from 5 subjects. All resultant cells had 16 amino acids in their heavy chain CDR3s, with the disulfide bond motif present, and 9 amino acids in their light chain CDR3s.

Selected sequences were aligned and visualized using ALINE (Bond and Schüttelkopf, 2009).

Fab expression and purification

For Fab production the genes for the heavy- and light-chain variable domains of S2E12 (Tortorici et al., 2020) and 2C08 (Turner et al., 2021) were synthesized and codon optimized by Integrated DNA Technologies and subcloned into pVRC protein expression vectors containing human heavy- and light-chain constant domains, as previously described (Bajic and Harrison, 2021; Bajic et al., 2019). Heavy-chain constructs for Fab production contained an HRV 3C-cleavable His6X tag. Constructs were confirmed by Sanger sequencing (Psomagen). Fabs were produced by transient transfection in suspension Expi293 cells using polyethylenamine (PEI, Polysciences). Supernatants were harvested 4-5 days later and clarified by centrifugation. Fabs were purified using Co2+-NTA TALON resin (Takara) followed by gel filtration chromatography on Superdex 200 Increase (GE Healthcare) in 10 mM Tris-HCl, 150 mM NaCl at pH 7.5. For BLI and cryoelectron microscopy the tags were removed using HRV 3C protease (ThermoScientific) and the protein re-purified using Co2+-NTA TALON resin to remove the protease, tag and non-cleaved protein.

Biolayer interferometry competition assays

Biolayer interferometry experiments were performed using a BLItz instrument (fortéBIO, Sartorius). For 2C08/hACE2 competition, polyhistidine-tagged Fab (2C08) was immobilized on Ni-NTA biosensors at 10 μg/mL and SARS-CoV-2 RBD was supplied as analyte at 5μM alone or pre-mixed with hACE2-Fc at different concentrations. Maximal signal (Rmax) at steady state in the absence of hACE2 and the same time points with varying concentration of hACE2 were used to plot the concentration-dependent competition of 2C08 with hACE2. For S2E12/2C08 competition, polyhistidine-tagged Fab (S2E12) was immobilized on Ni-NTA biosensors at 10 μg/mL and SARS-CoV-2 RBD was supplied as analyte at 5μM alone or pre-mixed with 2C08 (Polyhistidine-tag removed) at different concentrations. Maximal signal (Rmax) at steady state in the absence of 2C08 and the same time points with varying concentration of 2C08 were used to plot the concentration-dependent competition of S2E12 with 2C08. All experiments were performed in TBS at pH 7.5 and at room temperature.

Cryoelectron microscopy

SARS-CoV-2 HP spike was incubated with 2C08 Fab at 1.2 mg/mL with a molar ratio of Fab:Spike at 1.2:1 for 20 min at 4°C and 3 μL were applied and subsequently blotted for 2 s at blot force 1 on UltrAuFoil R1.2/1.3 grids (Quantifoil) then plunge-frozen in liquid ethane using an FEI Vitrobot Mark IV. Grids were then imaged on a Titan Krios microscope operated at 300 kV and equipped with a Gatan K3 Summit direct detector. 6,088 movies were collected in counting mode at 16e−/pix/s at a magnification of 64,000 corresponding to a calibrated pixel size of 1.076 Å/pixel with a defocus range of –2.5 to –0.8 μm.

Raw micrographs were aligned using MotionCorr2 (Zheng et al., 2017). Aligned micrographs were converted to png using Topaz (Bepler et al., 2019) then manually screened for ice contamination and complex degradation. Contrast transfer function for 4,433 cleaned micrographs were estimated using GCTF (Zhang, 2016). 602,948 particles were picked using Topaz with a model trained on a different SARS-CoV-2 spike-Fab complex. Data processing was performed using Relion (Scheres, 2012). Picked particles were binned to ~12Å/pixel and subjected to a 2D classification. 352,245 selected particles were then extracted to ~6Å/pixel then subjected to a second 2D classification of which 72,098 particles showing side-views were selected.

Quantification and statistical analysis

Statistical analyses were performed in GraphPad Prism (v8). The statistical details of experiments can be found in the figure legends.

Acknowledgments

The Vero-TMPRSS2 cells were kindly provided by S. Ding (Washington University School of Medicine, St. Louis, MO). The clinical sample for isolation of the B.1.617.2 variant was kindly provided by A. Patel (Poplar Healthcare, Memphis, TN). We thank W. Kim for helpful discussions. Some of this work was performed at the National Center for CryoEM Access and Training (NCCAT) and the Simons Electron Microscopy Center located at the New York Structural Biology Center, supported by the NIH Common Fund Transformative High Resolution Cryo-Electron Microscopy program (U24 GM129539) and by grants from the Simons Foundation (SF349247) and NY State Assembly Majority. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of NIAID or NIH. The Ellebedy laboratory was supported by NIAID grants U01AI141990 and U01AI150747 and NIAID Centers of Excellence for Influenza Research and Surveillance contract HHSN272201400006C. The Ellebedy and Krammer laboratories were supported by NIAID Centers of Excellence for Influenza Research and Surveillance contract HHSN272201400008C and NIAID Collaborative Influenza Vaccine Innovation Centers contract 75N93019C00051. The Diamond laboratory was supported by NIH contract 75N93019C00062 and grant R01 AI157155. The Boon laboratory was supported by NIH grants R01-AI118938 and U01-AI151810 and the Children's Discovery Institute grant PDII2018702. The Webby laboratory was supported by the NIAID Centers of Excellence for Influenza Research and Response contract 75N93021C00016. The Shi laboratory was supported by NIH grants AI134907 and UL1TR001439 and awards from the Sealy & Smith Foundation, Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation, and the Summerfield Roberts Foundation. The SARS-CoV-2 vaccine study was in part supported by NIH/National Center for Advancing Translational Sciences grant UL1 TR002345. J.S.T. was supported by NIAID 5T32CA009547. J.B.C. was supported by a Helen Hay Whitney postdoctoral fellowship.

Author contributions

A.J.S. and J.S.T. isolated the antibodies. A.J.S., Z.L., I.D.A., R.E.C., A.J., T.L.B., T.L.D., W.B.A., J.B.C, and L.A.V. functionally characterized the mAbs in vitro and in vivo. J.Q.Z. analyzed BCR repertoire data. D.C.A. and C.G.A. performed structural analyses. T.L., M.T. and F.A. expressed and purified the mAbs and recombinant viral proteins. T.J. and T.F. isolated the B.1.617.2 variant virus. A.J.S. and J.S.T. compiled and analyzed data. J.A.O. and R.M.P. supervised the vaccination study. P.-Y.S., R.J.W., and F.K. provided critical reagents. S.P.J.W. supervised the mapping analysis. G.B. supervised the structural analysis. M.S.D. and A.C.M.B. supervised the in vitro and in vivo analyses, respectively. A.H.E. conceptualized the study and wrote the manuscript with input from all co-authors.

Declaration of interests

The Ellebedy laboratory received funding under sponsored research agreements that are unrelated to the data presented in the current study from Emergent BioSolutions and from AbbVie. A.H.E. is a consultant for Mubadala Investment Company and the founder of ImmuneBio Consulting LLC. M.S.D. is a consultant for Inbios, Vir Biotechnology, Fortress Biotech, Carnival Corporation and on the Scientific Advisory Board of Moderna and Immunome. The Diamond laboratory has received unrelated sponsored research agreements from Moderna, Vir Biotechnology, and Emergent BioSolutions. The Boon laboratory has received unrelated funding support in sponsored research agreements from AI Therapeutics, GreenLight Biosciences Inc., and Nano targeting & Therapy Biopharma Inc. The Boon laboratory has received funding support from AbbVie Inc., for the commercial development of a SARS-CoV-2 mAb. A.J.S., J.S.T., W.B.A., J.B.C., S.P.J.W., M.S.D., A.C.M.B., and A.H.E. are recipients of a licensing agreement with Abbvie Inc., for commercial development of a SARS-CoV-2 mAb. A patent application related to this work has been filed by Washington University School of Medicine. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines, which list Florian Krammer as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020) and is currently consulting for Pfizer, Seqirus, and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. The Shi laboratory has received sponsored research agreements from Pfizer, Gilead, Merck, and IGM Sciences Inc. The Whelan laboratory has received unrelated funding support in sponsored research agreements with Vir Biotechnology, AbbVie, and sAB therapeutics. All other authors declare no conflict of interest.

Published: August 17, 2021

Footnotes

Supplemental information can be found online at https://doi.org/10.1016/j.immuni.2021.08.013.

Supplemental information

Document S1. Figures S1–S3 and Tables S1–S3
mmc1.pdf (1.6MB, pdf)
Document S2. Article plus supplemental information
mmc2.pdf (3.3MB, pdf)

Data and code availability

  • •

    Raw and processed bulk sequencing BCR reads are deposited at Sequence Read Archive and Zenodo, respectively, and are publicly available as of the date of publication. Accession numbers and DOIs are listed in the key resources table. This paper also analyzes existing, publicly available data. Accession numbers and DOIs are listed in the key resources table.

  • •

    All original code has been deposited at Zenodo and is publicly available as of the date of publication. DOI is listed in the key resources table.

  • •

    Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

References

  1. Alsoussi W.B., Turner J.S., Case J.B., Zhao H., Schmitz A.J., Zhou J.Q., Chen R.E., Lei T., Rizk A.A., McIntire K.M., et al. A potently neutralizing antibody protects mice against SARS-CoV-2 infection. J. Immunol. 2020;205:915–922. doi: 10.4049/jimmunol.2000583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Amanat F., Stadlbauer D., Strohmeier S., Nguyen T.H.O., Chromikova V., McMahon M., Jiang K., Arunkumar G.A., Jurczyszak D., Polanco J., et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26:1033–1036. doi: 10.1038/s41591-020-0913-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Amanat F., Thapa M., Lei T., Ahmed S.M.S., Adelsberg D.C., Carreño J.M., Strohmeier S., Schmitz A.J., Zafar S., Zhou J.Q., et al. Personalized Virology Initiative SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell. 2021;184:3936–3948.e10. doi: 10.1016/j.cell.2021.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Andreano E., Nicastri E., Paciello I., Pileri P., Manganaro N., Piccini G., Manenti A., Pantano E., Kabanova A., Troisi M., et al. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell. 2021;184:1821–1835.e16. doi: 10.1016/j.cell.2021.02.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. COVE Study Group Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bajic G., Harrison S.C. Antibodies that engage the hemagglutinin receptor-binding site of influenza B viruses. ACS Infect. Dis. 2021;7:1–5. doi: 10.1021/acsinfecdis.0c00726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bajic G., Maron M.J., Adachi Y., Onodera T., McCarthy K.R., McGee C.E., Sempowski G.D., Takahashi Y., Kelsoe G., Kuraoka M., Schmidt A.G. Influenza antigen engineering focuses immune responses to a subdominant but broadly protective viral epitope. Cell Host Microbe. 2019;25:827–835.e6. doi: 10.1016/j.chom.2019.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bepler T., Morin A., Rapp M., Brasch J., Shapiro L., Noble A.J., Berger B. Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographs. Nat. Methods. 2019;16:1153–1160. doi: 10.1038/s41592-019-0575-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bond C.S., Schüttelkopf A.W. ALINE: a WYSIWYG protein-sequence alignment editor for publication-quality alignments. Acta Crystallogr. D Biol. Crystallogr. 2009;65:510–512. doi: 10.1107/S0907444909007835. [DOI] [PubMed] [Google Scholar]
  10. Brouwer P.J.M., Caniels T.G., van der Straten K., Snitselaar J.L., Aldon Y., Bangaru S., Torres J.L., Okba N.M.A., Claireaux M., Kerster G., et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369:643–650. doi: 10.1126/science.abc5902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Case J.B., Rothlauf P.W., Chen R.E., Liu Z., Zhao H., Kim A.S., Bloyet L.-M., Zeng Q., Tahan S., Droit L., et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host Microbe. 2020;28:475–485.e5. doi: 10.1016/j.chom.2020.06.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chan J.F.-W., Yuan S., Kok K.-H., To K.K.-W., Chu H., Yang J., Xing F., Liu J., Yip C.C.-Y., Poon R.W.-S., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–523. doi: 10.1016/S0140-6736(20)30154-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Chen P., Nirula A., Heller B., Gottlieb R.L., Boscia J., Morris J., Huhn G., Cardona J., Mocherla B., Stosor V., et al. BLAZE-1 Investigators SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N. Engl. J. Med. 2021;384:229–237. doi: 10.1056/NEJMoa2029849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Chen R.E., Zhang X., Case J.B., Winkler E.S., Liu Y., VanBlargan L.A., Liu J., Errico J.M., Xie X., Suryadevara N., et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 2021;27:717–726. doi: 10.1038/s41591-021-01294-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chen R.E., Winkler E.S., Case J.B., Aziati I.D., Bricker T.L., Joshi A., Darling T.L., Ying B., Errico J.M., Shrihari S., et al. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature. 2021;596:103–108. doi: 10.1038/s41586-021-03720-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Corrie B.D., Marthandan N., Zimonja B., Jaglale J., Zhou Y., Barr E., Knoetze N., Breden F.M.W., Christley S., Scott J.K., et al. iReceptor: A platform for querying and analyzing antibody/B-cell and T-cell receptor repertoire data across federated repositories. Immunol Rev. 2018;284:24–41. doi: 10.1111/imr.12666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Dagan N., Barda N., Kepten E., Miron O., Perchik S., Katz M.A., Hernán M.A., Lipsitch M., Reis B., Balicer R.D. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N. Engl. J. Med. 2021;384:1412–1423. doi: 10.1056/NEJMoa2101765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Davies N.G., Abbott S., Barnard R.C., Jarvis C.I., Kucharski A.J., Munday J.D., Pearson C.A.B., Russell T.W., Tully D.C., Washburne A.D., et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372:eabg3055. doi: 10.1126/science.abg3055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Dejnirattisai W., Zhou D., Ginn H.M., Duyvesteyn H.M.E., Supasa P., Case J.B., Zhao Y., Walter T.S., Mentzer A.J., Liu C., et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell. 2021;184:2183–2200.e22. doi: 10.1016/j.cell.2021.02.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Dong J., Zost S.J., Greaney A.J., Starr T.N., Dingens A.S., Chen E.C., Chen R.E., Case J.B., Sutton R.E., Gilchuk P., et al. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv. 2021 doi: 10.1101/2021.01.27.428529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Edara V.-V., Pinsky B.A., Suthar M.S., Lai L., Davis-Gardner M.E., Floyd K., Flowers M.W., Wrammert J., Hussaini L., Ciric C.R., et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. N. Engl. J. Med. 2021;385:664–666. doi: 10.1056/NEJMc2107799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Edgar R.C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32:1792–1797. doi: 10.1093/nar/gkh340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. U.S. Food & Drug Administration . 2021. FDA Recommendations for Investigational COVID-19 Convalescent Plasma.http://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-applications-inds-cber-regulated-products/recommendations-investigational-covid-19-convalescent-plasma [Google Scholar]
  24. Galson J.D., Schaetzle S., Bashford-Rogers R.J.M., Raybould M.I.J., Kovaltsuk A., Kilpatrick G.J., Minter R., Finch D.K., Dias J., James L.K., et al. Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures. Front. Immunol. 2020;11:605170. doi: 10.3389/fimmu.2020.605170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Goel R.R., Apostolidis S.A., Painter M.M., Mathew D., Pattekar A., Kuthuru O., Gouma S., Hicks P., Meng W., Rosenfeld A.M., et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci Immunol. 2021;6:eabi6950. doi: 10.1126/sciimmunol.abi6950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Gottlieb R.L., Nirula A., Chen P., Boscia J., Heller B., Morris J., Huhn G., Cardona J., Mocherla B., Stosor V., et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325:632–644. doi: 10.1001/jama.2021.0202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Gupta N.T., Vander Heiden J.A., Uduman M., Gadala-Maria D., Yaari G., Kleinstein S.H. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. Bioinformatics. 2015;31:3356–3358. doi: 10.1093/bioinformatics/btv359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Han X., Wang Y., Li S., Hu C., Li T., Gu C., Wang K., Shen M., Wang J., Hu J., et al. A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2. Front. Immunol. 2021;12:653189. doi: 10.3389/fimmu.2021.653189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hsieh C.-L., Goldsmith J.A., Schaub J.M., DiVenere A.M., Kuo H.-C., Javanmardi K., Le K.C., Wrapp D., Lee A.G., Liu Y., et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020;369:1501–1505. doi: 10.1126/science.abd0826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Jackson L.A., Anderson E.J., Rouphael N.G., Roberts P.C., Makhene M., Coler R.N., McCullough M.P., Chappell J.D., Denison M.R., Stevens L.J., et al. mRNA-1273 Study Group An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N. Engl. J. Med. 2020;383:1920–1931. doi: 10.1056/NEJMoa2022483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W., Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., et al. Sheffield COVID-19 Genomics Group Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020;182:812–827.e19. doi: 10.1016/j.cell.2020.06.043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–527. doi: 10.1038/s41586-020-2798-3. [DOI] [PubMed] [Google Scholar]
  33. Kreer C., Zehner M., Weber T., Ercanoglu M.S., Gieselmann L., Rohde C., Halwe S., Korenkov M., Schommers P., Vanshylla K., et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell. 2020;182:843–854.e12. doi: 10.1016/j.cell.2020.06.044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Kreye J., Reincke S.M., Kornau H.-C., Sánchez-Sendin E., Corman V.M., Liu H., Yuan M., Wu N.C., Zhu X., Lee C.D., et al. A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model. Cell. 2020;183:1058–1069.e19. doi: 10.1016/j.cell.2020.09.049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K.S.M., Lau E.H.Y., Wong J.Y., et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N. Engl. J. Med. 2020;382:1199–1207. doi: 10.1056/NEJMoa2001316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Liu Y., Liu J., Xia H., Zhang X., Fontes-Garfias C.R., Swanson K.A., Cai H., Sarkar R., Chen W., Cutler M., et al. Neutralizing Activity of BNT162b2-Elicited Serum. N. Engl. J. Med. 2021;384:1466–1468. doi: 10.1056/NEJMc2102017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Liu Z., VanBlargan L.A., Bloyet L.-M., Rothlauf P.W., Chen R.E., Stumpf S., Zhao H., Errico J.M., Theel E.S., Liebeskind M.J., et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021;29:477–488.e4. doi: 10.1016/j.chom.2021.01.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Nielsen S.C.A., Yang F., Jackson K.J.L., Hoh R.A., Röltgen K., Jean G.H., Stevens B.A., Lee J.-Y., Rustagi A., Rogers A.J., et al. Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2. Cell Host Microbe. 2020;28:516–525.e5. doi: 10.1016/j.chom.2020.09.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Nonaka C.K.V., Franco M.M., Gräf T., de Lorenzo Barcia C.A., de Ávila Mendonça R.N., de Sousa K.A.F., Neiva L.M.C., Fosenca V., Mendes A.V.A., de Aguiar R.S., et al. Genomic evidence of SARS-CoV-2 reinfection involving E484K spike mutation, Brazil. Emerg. Infect. Dis. 2021;27:1522–1524. doi: 10.3201/eid2705.210191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Oude Munnink B.B., Sikkema R.S., Nieuwenhuijse D.F., Molenaar R.J., Munger E., Molenkamp R., van der Spek A., Tolsma P., Rietveld A., Brouwer M., et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science. 2021;371:172–177. doi: 10.1126/science.abe5901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Pappas L., Foglierini M., Piccoli L., Kallewaard N.L., Turrini F., Silacci C., Fernandez-Rodriguez B., Agatic G., Giacchetto-Sasselli I., Pellicciotta G., et al. Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature. 2014;516:418–422. doi: 10.1038/nature13764. [DOI] [PubMed] [Google Scholar]
  42. Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G., Zhang X., Muruato A.E., Zou J., Fontes-Garfias C.R., et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592:116–121. doi: 10.1038/s41586-020-2895-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. C4591001 Clinical Trial Group Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Robbiani D.F., Gaebler C., Muecksch F., Lorenzi J.C.C., Wang Z., Cho A., Agudelo M., Barnes C.O., Gazumyan A., Finkin S., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584:437–442. doi: 10.1038/s41586-020-2456-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Rogers T.F., Zhao F., Huang D., Beutler N., Burns A., He W.T., Limbo O., Smith C., Song G., Woehl J., et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369:956–963. doi: 10.1126/science.abc7520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Scheid J.F., Barnes C.O., Eraslan B., Hudak A., Keeffe J.R., Cosimi L.A., Brown E.M., Muecksch F., Weisblum Y., Zhang S., et al. B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell. 2021;184:3205–3221.e24. doi: 10.1016/j.cell.2021.04.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Scheres S.H.W. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 2012;180:519–530. doi: 10.1016/j.jsb.2012.09.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Shu Y., McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to reality. Euro Surveill. 2017;22:30494. doi: 10.2807/1560-7917.ES.2017.22.13.30494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Sia S.F., Yan L.M., Chin A.W.H., Fung K., Choy K.T., Wong A.Y.L., Kaewpreedee P., Perera R.A.P.M., Poon L.L.M., Nicholls J.M., et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020;583:834–838. doi: 10.1038/s41586-020-2342-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Singer J., Gifford R., Cotten M., Robertson D. CoV-GLUE: A Web Application for Tracking SARS-CoV-2 Genomic Variation. Preprint. 2020 doi: 10.20944/preprints202006.0225.v1. [DOI] [Google Scholar]
  51. Stadlbauer D., Amanat F., Chromikova V., Jiang K., Strohmeier S., Arunkumar G.A., Tan J., Bhavsar D., Capuano C., Kirkpatrick E., et al. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr. Protoc. Microbiol. 2020;57:e100. doi: 10.1002/cpmc.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V., Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021 doi: 10.1038/s41586-021-03402-9. [DOI] [PubMed] [Google Scholar]
  53. Tortorici M.A., Beltramello M., Lempp F.A., Pinto D., Dang H.V., Rosen L.E., McCallum M., Bowen J., Minola A., Jaconi S., et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science. 2020;370:950–957. doi: 10.1126/science.abe3354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Turner J.S., O’Halloran J.A., Kalaidina E., Kim W., Schmitz A.J., Zhou J.Q., Lei T., Thapa M., Chen R.E., Case J.B., et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021;596:109–113. doi: 10.1038/s41586-021-03738-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Wang P., Nair M.S., Liu L., Iketani S., Luo Y., Guo Y., Wang M., Yu J., Zhang B., Kwong P.D., et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593:130–135. doi: 10.1038/s41586-021-03398-2. [DOI] [PubMed] [Google Scholar]
  56. Wang Z., Schmidt F., Weisblum Y., Muecksch F., Barnes C.O., Finkin S., Schaefer-Babajew D., Cipolla M., Gaebler C., Lieberman J.A., et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616–622. doi: 10.1038/s41586-021-03324-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Weinreich D.M., Sivapalasingam S., Norton T., Ali S., Gao H., Bhore R., Musser B.J., Soo Y., Rofail D., Im J., et al. Trial Investigators REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N. Engl. J. Med. 2021;384:238–251. doi: 10.1056/NEJMoa2035002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Wheatley A.K., Whittle J.R.R., Lingwood D., Kanekiyo M., Yassine H.M., Ma S.S., Narpala S.R., Prabhakaran M.S., Matus-Nicodemos R.A., Bailer R.T., et al. H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem. J. Immunol. 2015;195:602–610. doi: 10.4049/jimmunol.1402835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Wilson P.C., Andrews S.F. Tools to therapeutically harness the human antibody response. Nat. Rev. Immunol. 2012;12:709–719. doi: 10.1038/nri3285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. World Health Organization WHO COVID-19 Dashboard. https://covid19.who.int/
  61. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., Chen X., Longo N.S., Louder M., McKee K., et al. NISC Comparative Sequencing Program Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 2011;333:1593–1602. doi: 10.1126/science.1207532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Yuan M., Wu N.C., Zhu X., Lee C.-C.D., So R.T.Y., Lv H., Mok C.K.P., Wilson I.A. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020;368:630–633. doi: 10.1126/science.abb7269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Zang R., Gomez Castro M.F., McCune B.T., Zeng Q., Rothlauf P.W., Sonnek N.M., Liu Z., Brulois K.F., Wang X., Greenberg H.B., et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol. 2020;5:eabc3582. doi: 10.1126/sciimmunol.abc3582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Zhang K. Gctf: Real-time CTF determination and correction. J. Struct. Biol. 2016;193:1–12. doi: 10.1016/j.jsb.2015.11.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Zheng S.Q., Palovcak E., Armache J.-P., Verba K.A., Cheng Y., Agard D.A. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods. 2017;14:331–332. doi: 10.1038/nmeth.4193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Zhou T., Lynch R.M., Chen L., Acharya P., Wu X., Doria-Rose N.A., Joyce M.G., Lingwood D., Soto C., Bailer R.T., et al. NISC Comparative Sequencing Program Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell. 2015;161:1280–1292. doi: 10.1016/j.cell.2015.05.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Zhou P., Yang X.-L., Wang X.-G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Zost S.J., Gilchuk P., Case J.B., Binshtein E., Chen R.E., Nkolola J.P., Schäfer A., Reidy J.X., Trivette A., Nargi R.S., et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584:443–449. doi: 10.1038/s41586-020-2548-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Zost S.J., Gilchuk P., Chen R.E., Case J.B., Reidy J.X., Trivette A., Nargi R.S., Sutton R.E., Suryadevara N., Chen E.C., et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat. Med. 2020;26:1422–1427. doi: 10.1038/s41591-020-0998-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Document S1. Figures S1–S3 and Tables S1–S3
mmc1.pdf (1.6MB, pdf)
Document S2. Article plus supplemental information
mmc2.pdf (3.3MB, pdf)

Data Availability Statement

  • •

    Raw and processed bulk sequencing BCR reads are deposited at Sequence Read Archive and Zenodo, respectively, and are publicly available as of the date of publication. Accession numbers and DOIs are listed in the key resources table. This paper also analyzes existing, publicly available data. Accession numbers and DOIs are listed in the key resources table.

  • •

    All original code has been deposited at Zenodo and is publicly available as of the date of publication. DOI is listed in the key resources table.

  • •

    Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Articles from Immunity are provided here courtesy of Elsevier

RESOURCES